ensitrelvir

Ensitrelvir is an oral small-molecule antiviral developed by Shionogi for treatment of severe acute respiratory syndrome coronavirus 2 infection. It is a non-covalent 3C-like protease inhibitor that blocks the viral main protease required for cleavage of viral polyproteins and thereby inhibits SARS-CoV-2 replication. Public sources in the provided context identify ensitrelvir under the code name S-217622, note its discovery through joint research between Shionogi and Hokkaido University, and describe Japanese approval for mild to moderate COVID-19. The program has also been studied in outpatient treatment, household post-exposure prophylaxis, hospitalized COVID-19, Long COVID, and pharmacokinetic and drug-drug interaction studies, with licensing arrangements involving Medicines Patent Pool, Juniper Biologics, and partners in China.

Brand names

Xocova

Other names

ensitrelvir fumaric acid